Whether autologous or allogeneic – the science behind personalized medicines and CGT is changing lives. The possibilities are exciting as approvals have continued to increase year-on-year. The result? An uptick in clinical trials aimed at developing therapies for illnesses that may have previously been untreatable.
That’s good news for patients and caregivers, but keeping clinical trials moving and bringing treatments to market can be complicated. To begin with, because they are ‘personalized,’ requirements vary for each drug in terms of temperature and timing. There are a lot of moving parts, and certainly, there is no one-size-fits-all solution when it comes to logistics. That’s where detailed planning comes into play.
Listen in as Mike discusses the challenges of moving donor-based materials, the importance of having one, two, three or more backup plans, and how the right logistics partner can help biopharma companies work through options and make fast decisions to keep the supply chain moving.
